UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 89.6%

Neg 89.6% Neu 0% Pos 0%

UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.